Piramal Pharma Limited has informed the Exchange regarding a press release dated May 14, 2025, titled "Press Release and Investor Presentation Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended 31st March, 2025".
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Piramal Pharma announced its FY2025 results, reporting consolidated revenue of ₹9,151 Cr, up 12% YoY, crossing the $1 Billion mark for the first time. EBITDA grew 15% YoY to ₹1,580 Cr with margin expanding to 17% (from 12% in FY23), while profit after tax surged 411% to ₹91 Cr (low base due to prior year exceptional items). The CDMO segment led growth at 15% YoY (₹5,447 Cr), driven by a 50%+ jump in on-patent commercial manufacturing revenues to $179 Mn. The CHG segment grew 8% to ₹2,633 Cr, maintaining #1 US market share in Sevoflurane (44%) and Baclofen (75%), while India Consumer Healthcare crossed ₹1,000 Cr with 11% growth, led by a 20% rise in power brands. Net Debt/EBITDA improved sharply to 2.7x from 5.6x in FY23. The company has set FY2030 aspirations of $2 Bn+ revenue and 25% EBITDA margin.
The results show broad-based growth, margin expansion, and significant deleveraging, in line with management guidance. A 5x jump in net profit and 17% EBITDA margin reflect strong operational execution, likely to be viewed positively by investors. The reaffirmed $2 Bn revenue and 25% margin target for FY2030 signals management confidence, while the scheduled investor call on May 15, 2025 may drive near-term stock attention.